Pakola Steve's Form 4 filing
REGENXBIO Inc. (RGNX) · filed Jan 4, 2024
- Accession no.
- 0001562180-24-000252
- Filed
- Jan 4, 2024
- Trade date
- Jan 2-3, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $299.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pakola SteveCIK 0001700659 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2024 | Common Stock | FTax withholdingDisposed | −10,385 | $17.95 | −$186,410.75 | 92,378 | Direct | |
| Jan 2, 2024 | Common Stock | AGrant or awardAcquired | +32,051 | $0.00 | $0 | 124,429 | Direct | |
| Jan 3, 2024 | Common Stock | SSaleDisposed | −17,237 | $17.39F4 | −$299,751.43 | 107,192 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2024 | Common Stock | AGrant or awardAcquired | +50,875 | $0.00 | $0 | 50,875 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
This transaction was executed in multiple trades at prices ranging from $17.05 to $17.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.